Joseph Councill
Psychiatric/Mental Health · Bellevue, NENPI 1750704623
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AbbVie at 55.8% of the total. Reporting peaked in 2021 at $4,569 and has fallen 86.7% since, to $608 in 2025. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $45.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Supernus Pharmaceuticals, Inc.$509
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$482
- Vanda Pharmaceuticals Inc.$362
- Alkermes, Inc.$262
- Axsome Therapeutics, Inc.$242
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$3,85051%
- Food & beverage$3,68548%
- Education$861%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $4,254 |
| Supernus Pharmaceuticals, Inc. | 18 | $509 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $482 |
| Vanda Pharmaceuticals Inc. | 12 | $362 |
| Alkermes, Inc. | 11 | $262 |
| Axsome Therapeutics, Inc. | 7 | $242 |
| Otsuka America Pharmaceutical, Inc. | 11 | $219 |
| Johnson & Johnson | 2 | $218 |
| Sunovion Pharmaceuticals Inc. | 10 | $179 |
| Corium, LLC | 13 | $156 |
| E.r. Squibb & Sons, L.L.C. | 5 | $117 |
| Lundbeck LLC | 6 | $116 |
| Neos Therapeutics, LP | 5 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Harmony Biosciences LLC | 2 | $43 |
| Noven Therapeutics, LLC | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,621 in reported general payments places this provider in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 21 | $455 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $239 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Bellevue
- Janette StallingsBellevue$7K
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.